WallStreetZenWallStreetZen

NYSE: MD
MEDNAX INC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for MD

Based on 5 analysts offering 12 month price targets for MEDNAX INC.
Min Forecast
$20.00+7.82%
Avg Forecast
$27.20+46.63%
Max Forecast
$32.00+72.51%

Should I buy or sell MD stock?

Based on 5 analysts offering ratings for MEDNAX INC.
Buy
Strong Buy
0 analysts 0%
Buy
3 analysts 60%
Hold
2 analysts 40%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

MD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
SVB Leerink
Top 37%
64
HoldMaintains$20.00+7.82%2022-05-12
Credit Suisse
Bottom 9%
9
BuyMaintains$30.00+61.73%2022-05-03
Mizuho
Top 17%
84
HoldMaintains$23.00+23.99%2022-05-02
Credit Suisse
Top 5%
96
BuyMaintains$31.00+67.12%2022-02-23
Credit Suisse
Bottom 41%
41
BuyMaintains$32.00+72.51%2021-12-22
Anonymous
Citigroup
HoldMaintains$34.00+83.29%2021-05-24

1 of 1

Forecast return on equity

Is MD forecast to generate an efficient return?
Company
17.01%
Industry
-125.71%
Market
32.81%
MD's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MD forecast to generate an efficient return on assets?
Company
6.37%
Industry
8.41%
MD is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MD earnings per share forecast

What is MD's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$1.75
Avg 2 year Forecast
$1.86
Avg 3 year Forecast
$1.66

MD revenue forecast

What is MD's revenue in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
$2.0B+3.24%
Avg 2 year Forecast
$2.1B+9.19%
Avg 3 year Forecast
$2.3B+18.73%
MD's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MD revenue growth forecast

How is MD forecast to perform vs Medical Care Facilities companies and vs the US market?
Company
5.3%
Industry
8.34%
Market
9.2%
MD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MD vs Medical Care Facility Stocks

TickerPricePrice TargetUp/downsideConsensus
MD$18.55$27.20+46.63%Buy
TVTY$32.09$31.00-3.40%Hold
AMEH$32.47$92.00+183.34%Hold
MODV$100.40$150.00+49.40%Strong Buy
USPH$105.77$120.00+13.45%Buy
View Top Medical Care Facility Stocks

MEDNAX Stock Forecast FAQ

Is MEDNAX Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NYSE: MD) stock is to Buy MD stock.

Out of 5 analysts, 0 (0%) are recommending MD as a Strong Buy, 3 (60%) are recommending MD as a Buy, 2 (40%) are recommending MD as a Hold, 0 (0%) are recommending MD as a Sell, and 0 (0%) are recommending MD as a Strong Sell.

What is MD's earnings growth forecast for 2022-2024?

(NYSE: MD) MEDNAX's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Care Facilities industry's average forecast earnings growth rate of 4.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.78%.

MEDNAX's earnings in 2022 is $92,134,000.On average, 5 Wall Street analysts forecast MD's earnings for 2022 to be $152,707,567, with the lowest MD earnings forecast at $143,108,806, and the highest MD earnings forecast at $157,943,255. On average, 6 Wall Street analysts forecast MD's earnings for 2023 to be $162,306,329, with the lowest MD earnings forecast at $138,745,733, and the highest MD earnings forecast at $173,650,319.

In 2024, MD is forecast to generate $144,854,035 in earnings, with the lowest earnings forecast at $144,854,035 and the highest earnings forecast at $144,854,035.

What is MD's revenue growth forecast for 2022-2024?

(NYSE: MD) MEDNAX's forecast annual revenue growth rate of 5.3% is not forecast to beat the US Medical Care Facilities industry's average forecast revenue growth rate of 8.34%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.2%.

MEDNAX's revenue in 2022 is $1,946,667,000.On average, 6 Wall Street analysts forecast MD's revenue for 2022 to be $175,375,740,317, with the lowest MD revenue forecast at $173,676,497,770, and the highest MD revenue forecast at $178,179,189,467. On average, 6 Wall Street analysts forecast MD's revenue for 2023 to be $185,477,389,521, with the lowest MD revenue forecast at $177,976,742,864, and the highest MD revenue forecast at $189,414,975,958.

In 2024, MD is forecast to generate $201,678,702,530 in revenue, with the lowest revenue forecast at $201,678,702,530 and the highest revenue forecast at $201,678,702,530.

What is MD's forecast return on assets (ROA) for 2022-2025?

(NYSE: MD) forecast ROA is 6.37%, which is lower than the forecast US Medical Care Facilities industry average of 8.41%.

What is MD's Price Target?

According to 5 Wall Street analysts that have issued a 1 year MD price target, the average MD price target is $27.20, with the highest MD stock price forecast at $32.00 and the lowest MD stock price forecast at $20.00.

On average, Wall Street analysts predict that MEDNAX's share price could reach $27.20 by May 12, 2023. The average MEDNAX stock price prediction forecasts a potential upside of 46.63% from the current MD share price of $18.55.

What is MD's Earnings Per Share (EPS) forecast for 2022-2024?

(NYSE: MD) MEDNAX's current Earnings Per Share (EPS) is -$0.55. On average, analysts forecast that MD's EPS will be $1.75 for 2022, with the lowest EPS forecast at $1.64, and the highest EPS forecast at $1.81. On average, analysts forecast that MD's EPS will be $1.86 for 2023, with the lowest EPS forecast at $1.59, and the highest EPS forecast at $1.99. In 2024, MD's EPS is forecast to hit $1.66 (min: $1.66, max: $1.66).

What is MD's forecast return on equity (ROE) for 2022-2025?

(NYSE: MD) forecast ROE is 17.01%, which is considered weak.
©2022 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending StocksStock Market SectorsStock Market Industries
Analysts
Top Performing Analysts
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.